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                                                           Abstract 
Background:  Opioid abuse is a challenging health care concern, and  has been identified as a 
national public health issue. The prevalence of illicit fentanyl and prescription pain medication in 
our society are related to a multitude of factors which have impacted many lives and triggered a 
national epidemic despite experts' preventative measures and treatment recommendations. 
Purpose: A quality improvement (QI) project was designed to enhance the assessment of 
patients suffering from opioid use disorder (OUD) with evidence-based screening tools to 
prevent opioid abuse among adult patients in a chronic care psychiatric hospital. Methods: The 
QI project integrated an educational intervention to an interdisciplinary team comprising of 
psychiatrists, psychologists, nurses, mental health counselors, and social workers. The project’s 
purpose was to improve the process of opioid abuse evaluation for clients with co-occurring 
mental illness and OUD at an inpatient psychiatric hospital. The DNP project included screening 
scales to identify and monitor six clients receiving medication-assisted treatment (MAT) for 
behavior change. A pre-intervention questionnaire and a post-test questionnaire were initiated at 
the beginning prior to and following the presentation of education intervention, respectively, to 
measure the knowledge gained. Results and Conclusion: The clinician participants reported 
enhanced knowledge in assessment, identification, and referral of clients with OUD to specialty 
treatment services. Additionally, the client participants demonstrated increased knowledge of 
opioid abuse risk and the need to continue MAT after discharge. 
         Keywords: Opioid use disorder and co-occurring mental illness, medicated-assisted 




A Quality Improvement Project for Opioid Use Disorder at a Psychiatric Hospital  
in Western Massachusetts 
                                                          Introduction 
Problem and Purpose  
Opioid use disorder (OUD) has been categorized as a public health emergency (Duber et 
al., 2018). According to the National Institute of Health (NIH, 2019), drug abuse, opioid 
dependence, and overdose related to abusing opioid prescriptions, heroin, and fentanyl have 
prompted a national epidemic in the U.S. with over 130 deaths per day. The Centers for Disease 
Control and Prevention (CDC, 2016) has published clinical practice guidelines to help in the 
treatment and prevention of drug abuse and overdose. 
      Western Massachusetts has been identified by the Massachusetts Department of Public 
Health as having the second-highest number of opioid-related deaths in the state of 
Massachusetts. Opioid abuse in the general population and illegal prescription painkillers 
(namely, fentanyl and heroin in the community where the hospital is situated) are the 
overwhelming ecological influences. The public psychiatric hospital in western Massachusetts, 
was the setting for the project and serves individuals with various mental illness diagnoses. In 
addition to mental illness, the hospital had several episodes of clients overdose from illicit opioid 
abuse and two deaths in 2019(Curran, 2019). Patients at the hospital are usually not screened 
adequately with standardized opioid assessment scales during the admission evaluation. 
Moreover, the issues of patients craving for illegal substances were not correctly addressed and 
treated since most of the psychiatric clinicians did not have the authority to prescribe medication 
assisted treatment for clients with opioid use disorder at that time. Subsequently, opioid abuse 
persists at the project site because patients with this diagnosis are unaware of the problem. 
Furthermore, some inpatient psychiatric facility clients with opioid addiction are ambivalent 
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about engaging in the available treatment with psychotherapy intervention without access to 
medication-assisted treatment during their hospitalization. 
 Medication-assisted treatment (MAT) utilizes medications such as buprenorphine, 
naltrexone, and methadone, combined with psychotherapy interventions and counseling to treat 
opioid use disorder (Substance Abuse and Mental Health Services Administration [SAMHSA], 
2021). Medication-assisted treatment is predominantly utilized to treat clients challenged with 
opioid abuse. The prescribed medication works to normalize brain chemistry, block the euphoric 
effects of opioids, liberate physical cravings, and stabilize body functions by eliminating the 
damaging elated effects of opioid abuse (SAMHSA, 2021). The evidence-based literature shows 
that a combination of early assessment to identify clients with OUD, medication, and 
psychotherapy intervention can be used to treat patients struggling with opioid use disorder 
successfully (SAMHSA, 2021). 
  On the other hand, the implementation of MAT is currently fragmented in underserved 
settings such as prisons and psychiatric hospitals. The gap between evidence-based information 
and the translation of this knowledge into clinical practice to improve care for patients at risk in a 
psychiatric hospital can be done by improving clinical skills through training. The educational 
component of this QI project includes how to properly use opioid assessment tools such as 
Screening, Brief Intervention, Referral to Treatment (SBIRT) and the Clinical Opiate 
Withdrawal Scale (COWS) (Rosenthal et al., 2018). The CDC (2016) recommendation also 
reveals that evidence-based practice should include counseling with motivational interviewing 
skills, clinical judgment, and easy access to MAT for patients with opioid use disorder (OUD).  
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Background 
         Opioid abuse disorder is prevalent among clients with a mental health condition. Han et al. 
(2017) reported that about 7.7 million adults suffer from a co-occurring psychiatric diagnosis and 
substance abuse in the U.S.and 38.4% of this population are ambivalent about engaging in 
treatment. The National Institute on Drug Abuse (2020) reported data from a nationwide sample 
that noted that people with mental illness were at increased risk for ingesting nonmedical 
prescription opioids. The interactions between psychiatric diagnoses and opioid abuse can 
exacerbate the symptoms of both disorders and predispose clients to the risk of overdose and 
subsequent death from opioids (Han et al., 2017). Besides, Velez et al. (2016) concluded that 
inpatient hospitalization is an appropriate timeframe to successfully reach patients who are 
indicated for substance abuse treatment, as they may comprehend that substance abuse has 
harmfully affected their wellbeing. The US Preventative Service Task Force [USPSTF] (2019) 
recommends OUD treatment, which involves assessing illicit drugs and the misuse of 
prescription drugs and subsequent referral for intervention to counteract drug abuse. 
 The Clinical Opiate Withdrawal Scale (COWS) is an 11-item tool designated for 
implementation by healthcare practitioners to assess and monitor signs and symptoms of opiate 
withdrawal in inpatient and outpatient settings (Tompkins et al., 2009). Several studies recognize 
the COWS as reliable (Wesson & Ling, 2003). Also, the Screening, Brief Intervention, and 
Referral to Treatment (SBIRT) tool is designed to provide early intervention and treatment for 
individuals diagnosed with substance abuse or clients at risk of displaying OUD (SAMHSA, 
2017). The approach utilizes procedures that assess and classify substance abuse, offer 
motivational interviewing techniques through counseling to enhance the client's insight into 
opioid abuse, and refer clients with OUD to extensive specialty treatment (SAMHSA, 2017). 
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Problem Statement 
     The opioid abuse epidemic has impacted society and resulted in drug overdose deaths 
reaching 63,632 in 2016, which is an estimated increase of 21.4% from the previous year (Duber 
et al., 2018). Also, Duber et al. reported that 66.4% of users died from illegal opioid abuse 
events, which represents an alarming annual increasing rate of 27.7% from 2015. Subsequently, 
Vashishtha et al. (2017) stated that the drug overdose death rate has exceeded the motor vehicle 
accidental death rate and the researchers classify drug overdose as the highest avoidable cause of 
death in America. Evidence from the literature supports a multifaceted intervention that includes 
early assessment for the misuse of illicit opioids and a subsequent recommendation for treatment 
that provides MAT, psychotherapy, and individual counseling (CDC, 2016; Duber et al., 2018; 
SAMHSA, 2021; USPSTF, 2019).  
Evidence-based findings from the literature endorse the appropriate use of opioid 
assessment screening scales like COWS and SBIRT to identify and refer patients with OUD to 
treatment (Rosenthal et al., 2018; Timko et al., 2016; Vashishtha et al., 2017). The primary focus 
of the Doctoral Nurse Practitioner (DNP) capstone project was to provide education for 
healthcare clinicians regarding how to appropriately use standardized screening opioid 
assessment scales in identifying patients with OUD before referring these patients for treatment 
that incorporates MAT with psychotherapy intervention. The goal of this kind of treatment is to 
decrease opioid abuse and overdoses within the psychiatric healthcare facility and inspire change 
in these clients. 
Review of the Literature 
 A comprehensive search of the literature on opioid abuse and opioid use disorder to obtain 
evidence for the review was initiated through the National Institute of Health [NIH], National 
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Library of Medicine website to retrieve applicable medical subject headings [MeSH] terms. The 
MeSH terms of opioid abuse/dependence, opioid overdose, and co-occurring psychiatric 
symptoms were applied to the Cumulative Index of Nursing and Allied Health Literature 
[CINAHL], PsycINFO, and MEDLINE databases. The following inclusive limiting filters were 
applied: (a) peer-reviewed English language research literature published from 2015 to 2019 and 
(b) randomized controlled trials. The search was unsuccessful and yielded three articles that did 
not meet the criteria of the search terms. 
        Subsequently, after consultation with the librarian at the University of Massachusetts 
Amherst Graduate Research Center, the MeSH term was paraphrased to opioid abuse and 
treatment intervention. The Cochrane Library was also used to simplify the search terms. The 
simplified MeSH terms were reapplied to CINAHL and PubMed of the National Library of 
Medicine separately. As a result, 167 articles were retrieved. Inclusion filters that consisted of 
free full-text research articles published in the English language within the past five years were 
utilized to reduce the number of articles to 20. At this point, the exclusion filters used were sex, 
geographic subset, publication type, a particular interest, and pregnancy. Other subjects such as 
HIV, Hepatitis C, co-occurring medical diagnoses, polysubstance abuse, and alcohol use disorder 
were excluded from the review. Of the 20 study articles identified in the search results, ten 
centered on opioid abuse and met the criteria for inclusion in the assessment of the literature.  
Synthesis of the Key Concepts of the Literature 
 The ten articles selected for the literature review consisted of two systematic reviews, one 
quasi-experimental non-randomized study, two non-experimental design studies, one quantitative 
randomized controlled trial (RCT), one QI study, and two expert opinion articles. In addition, 
this literature review included a concise assessment of the CDC’s (2016) clinical practice 
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guideline for prescribing opioids for chronic pain in outpatient settings. The following is a 
description of the significant results from these research findings.   
A study by Baird et al. (2019) assessed a safer opioid prescribing procedure for patients 
being released from a trauma service center. This quasi-experimental study examined safety 
concerns surrounding opioid prescribing for patients at risk of opioid abuse and overdose. They 
reviewed the electronic health records of two different trauma centers from 2014 to 2016 with a 
sample size of 191 (pre-intervention application) and 316 (post-intervention implementation) to 
identify patients at risk for opioid abuse. This research demonstrated that clinicians could 
identify best practice alerts to trigger naloxone prescriptions for patients at risk of opioid abuse. 
The findings also initiated opioid prescribing criteria within the trauma centers (Baird et al., 
2019). 
 Ronan and Herzig (2016) surveyed patient discharge records from 2002 to 2012 in the 
U.S.to determine the rate of hospitalization, infections associated with OUD, cost of treatment, 
and mortality rates among patients with OUD. The authors revealed that hospitalization and the 
cost of providing care for clients with OUD have significantly increased since 2002 with the 
government bearing the financial burden of cost. Bowles and Lankenau (2018) investigated 
opioid distribution methods in an opioid program tailored to educate and provide naloxone to 
patients with OUD to prevent overdose from opioids. The study has a significant implication 
regarding how to avoid injury and promote healthy behaviors among patients with OUD. 
However, the limitations of the research, such as its small sample size, bias, methods of data 
collection, and analysis, may have compromised the validity and confirmability of the results 
(Bowles & Lankenau, 2018).   
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Wasan et al. (2015) explored how psychiatric symptoms that produce adverse effects such 
as depression and anxiety can predict patients at risk of an OUD, especially for a patient on 
opioid treatment for chronic lower back pain (CLBP) as compared with a patient without 
psychiatric symptoms. Wasan et al. (2015) demonstrated that adverse effects such as depression 
and anxiety related to co-occurring mental illness diagnoses of depression and anxiety disorder 
are strong predictors of a poor treatment result with an opioid for patients with CLBP and a risk 
factor for opioid abuse.  
Rosenthal et al. (2018) identified a gap in knowledge regarding how to appropriately 
utilize the SBIRT opiate assessment tool and the COWS to evaluate clients with OUD. The study 
describes the wrong ways SBIRT and COWS have been used and the vulnerability showed by 
nurses in an inpatient facility before implementing a quality improvement project to train 
clinicians on how to use these assessment tools to identify patients with OUD and those with 
opiate withdrawal symptoms (Rosenthal et al., 2018). 
Timko et al. (2016) systematically reviewed and compared 55 studies on MAT therapy 
using buprenorphine, naltrexone, methadone, and behavioral treatment. The research report 
unfolded different rates of retention in the MAT program. The investigation of a MAT study 
from 2010 to 2014 by the authors revealed that patients with OUD could be clinically "managed 
to increase their retention in MAT and ultimately improve their quality of life" (Timko et al., 
2016, p. 9). 
Duber et al. (2018) found that eight million Americans, which represents an estimated 1.4 
percent of the national census aged 12 and older, abuse pain relievers. They also found that 
329,000 individuals aged 12 and above abuse heroin. Furthermore, in their systematic review, 
they reported that 2.1 million Americans abuse prescription opioids and approximately 135,000 
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were recorded as having initiated heroin abuse in 2015. Consequently, the researchers examined 
assessment tools such as the brief self-report tool with yes or no questions and the 5-point Likert 
scale used for OUD assessment and explored the prescription drug monitoring program (PDMP) 
to rule out drug-drug interaction. The study suggested strategies to treat patients withdrawing 
from opioids and identified MAT therapy as the treatment of choice for OUD patients in acute 
and chronic settings (Duber et al., 2018). 
Vashishtha et al. (2017) clearly described the global crisis of OUD and the implication for 
infectious diseases such as HIV/AIDs. The authors identified factors that impede the 
accessibility of MAT therapy to patients with OUD as follows: financial cost, lack of 
accessibility of MAT, and other systemic and environmental policies such as compliance with 
federal methadone laws, rigorous criteria for clinicians with prescriptive rights to obtain MAT 
certification waivers, a sidelined population, the stigma associated with OUD that prevents 
clients from engaging in treatment, lack of national health insurance, long waitlist, lack of 
integrated treatment center, very few addiction experts, and lack of federal and state funding for 
MAT therapy. The authors succinctly recommended the following: adequate government 
funding for treatment, the removal of barriers that impede healthcare providers from making 
MAT therapy available to patients with OUD, availability of programs or centers for MAT 
treatment in opioid-infested communities and neighborhoods, and the formulation of policies that 
legalize drug possession to enable OUD patients present from hideouts and engage in treatment 
to prevent HIV/AIDs (Vashishtha et al., 2017).  
     The developers of the CDC (2016) guideline revealed that opioids are not endorsed as an 
initial treatment for chronic pain for adults in outpatient settings and advised clinicians to use 
non-pharmacologic and non-opioid therapy in providing care for chronic pain for adult patients 
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in outpatient settings. The CDC (2016) opioid prescribing guideline specified criteria for using 
assessment tools and clinical judgment to evaluate clients at risk for opioid use disorder and 
prevent adverse events of opioid abuse and overdose. The guidelines advised clinicians to 
prescribe naloxone and opioids for patients with substance abuse history and refer clients with 
OUD for MAT.  
      In conclusion, the literature review reveals the magnitude of the opioid abuse crisis. The 
literature provided evidence to support the proposed intervention. Additionally, these findings 
describe various strategies to tackle the opioid abuse crisis by following evidence-based 
recommendations that include the appropriate utilization of opioid assessment tools such as the 
SBIRT and COWS to identify and refer patients withdrawing from opioids for treatment, as well 
as through clinical judgment of experts. They strongly endorse medication-assisted treatment 
therapy as the treatment of choice for a patient suffering from OUD (CDC, 2016; Rosenthal et 
al., 2018; Timko et al., 2016; Vashishtha et al., 2017).  
 In addition, the literature review identified and revealed barriers to implementing MAT 
therapy, such as systemic barriers, access to MAT therapy, and insurance cost (Vashishtha et al., 
2017). The evidence from the literature shows that clinicians should prescribe naloxone with 
opioids for patients at risk of OUD to mitigate the risk of overdose from opioids (Baird et al., 
2019; CDC, 2016; Ronan & Herzig, 2016). The evidence from the literature also reveals that 
clinicians should treat other psychiatric symptoms with psychoactive medications and use non-
opioid analgesics to treat patients with CLBP who have a co-occurring psychiatric disorder. This 
is because the negative effects that originate from psychiatric disorders such as depression and 
anxiety will produce poor outcomes with opioid treatment and predispose patients in this 
population to abuse opioids (CDC, 2016; Wasan et al., 2015). These recommendations provide 
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clinicians with some resources and means to use in response to the opioid epidemic crisis in 
America. 
Theoretical Framework/Evidence-Based Practice Model 
The conceptual framework underpinning the QI project is the transtheoretical behavioral 
change model (TTM) initially posited by Prochaska and DiClemente in 1982 (Appendix A). 
Prochaska et al. (1992) noted that people intentionally change and summarize the key 
components of the transtheoretical processes of change into pre-contemplation, contemplation, 
preparation, action, maintenance, and termination. This outline of the stages of change was 
detected in research with smokers trying to relinquish their own habit and smokers in specialized 
management programs. The authors noted that individuals were observed as advancing linearly 
from the stage of pre-contemplation to the stages of contemplation, preparation, action, and 
maintenance, and termination. 
According to Prochaska et al. (1992), the pre-contemplation stage in the trajectory of the 
change spectrum is the stage at which the individual has no plan to change his/her behavior in 
the immediate future. The individuals at this stage are grossly unaware of the need to change 
their habits, and they do not consider the behavior problematic. On the other hand, the 
researchers stated that contemplation is the phase in which individuals are mindful that difficulty 
in their behavior exists and are sincerely thinking about conquering it but have not yet dedicated 
themselves to take a responsible plan of action to overcome the problem. At this stage, 
individuals evaluate the pros and cons of the challenge and the solution to the difficulty 
(Prochaska et al., 1992). The authors described the preparation stage as the stage that merges 
purpose with behavior norms. In the preparation stage, the individual plans to act soon and may 
have worked toward taking the action and failed. People in this phase are experiencing and 
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expressing small positive changes (Prochaska et al., 1992). The action stage is when individuals 
adjust their conduct, practices, situation, and background to change the difficulties. In the action 
phase, the individual is committed to the change process and is taking positive steps in this 
direction.  
       The writers stated that maintenance is when individuals act to prevent setbacks and 
strengthen the benefits accomplished in the action phase and successfully terminate the behavior 
(Prochaska et al., 1992). The TTM demonstrates an understanding of when shifts in opinions, 
objectives, and performances occur. Thus, the TTM was utilized in this QI project because it 
involves screening modalities that identify adults with opioid abuse disorder in a chronic care 
psychiatric hospital. It also entails measures that encourage adults with OUD to change from 
abusing illegal opioids to abstaining from this behavior. The change process was initiated and 
accomplished in adults diagnosed with opioid abuse by the psychiatrist, psychiatric mental health 
nurses, clinical nurse specialists, social workers, psychologists, and registered nurses. The 
COWS and SBIRT assessment tools were the basis of the assessment of clients with opioid use 
disorder and early referral to treatment to prevent opioid abuse and accidental deaths.  
                                                               Methods 
   The quality improvement (QI) project design consisted of an educational intervention to 
16 healthcare providers in order to increase knowledge, skills, and confidence levels in assessing, 
identifying and treating those with dual diagnosis in a public inpatient psychiatry hospital. Data 
was collected by the DNP student through pre, and posttest surveys created by the DNP student. 
Literature substantiates using the Clinical Opiate Withdrawal Scale (COWS) and the Screening, 
Brief Intervention, and Referral to Treatment (SBIRT) scale in assessing, identifying and 
referring clients with opioid use disorder (OUD) to medication-assisted treatment, counseling 
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and a substance awareness group. The QI project provided an educational PowerPoint training to 
the participants prior to implementing the screening scales. Furthermore, the QI intervention also 
utilized the transtheoretical model of behavior change (TTM) to measure behavior change in six 
clients (Prochaska and DiClemente, 1982). The clients were selected by their clinicians as 
exhibiting a diagnosis of opioid use disorder (OUD) based on DSM-V criteria. To measure the 
outcome of this DNP project, the following instruments were utilized: a pre-test questionnaire 
and a post-test intervention survey which was administered following a presentation on OUD 
signs and symptoms, screening scales and treatment. 
Goals, Objectives, and Expected Outcomes 
       The overarching goal of the project was to provide education to healthcare clinicians 
concerning how to appropriately use standardized screening opioid assessment scales to identify 
patients with co-occurring OUD, offer brief intervention, and refer the patients for treatment in 
order to decrease opioid abuse and overdose within the psychiatric facility and inspire change in 
these clients. The treatment included medication-assisted treatment (MAT), individual 
counseling that incorporates motivational interviewing strategies and substance awareness group. 
The goals, of the QI project were as follows: 
Goal 1. The interdisciplinary team clinicians on Wards A2 and C3 of the psychiatric hospital 
were able to gain knowledge in OUD signs, symptoms, assessment, and identification and in the 
referral of clients to treatment with medication-assisted therapy, a substance awareness group, 
and individual counseling. 
Goal 2. The psychiatry clinicians were able to verbalize that client benefitted from MAT, the 
substance awareness group, and individual counseling. 
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Expected Outcome: The QI project implementation resulted in increased awareness among the 
participants of the signs and symptoms of OUD, screening scales, early diagnosis, and the 
treatment of clients as evidenced by positive self-report from data yielded from the completion of 
the survey and interviews.  
Population and Project Site  
The project was implemented on an inpatient public psychiatric hospital in a small town in 
western Massachusetts. The hospital provides acute and chronic psychiatric services to over 260 
adults and 60 teenagers with severe mental and emotional disorders. The patients come from 
various backgrounds and cultures. The services provided comprise psychiatric evaluation and 
treatment, psychotherapy intervention, forensic evaluation, and clients' commitment through the 
courts for treatment. In addition, substance abuse treatment with buprenorphine, methadone, and 
naltrexone is also offered and was added earlier this year after several occurrences of opioid 
abuse and overdose in the hospital. The project site also coordinates with other facilities to offer 
electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), medical assessment, 
and treatment for clients in need of such services.  
The healthcare providers on the two units include 3 psychiatrists, two on-call psychiatrists, 
and several psychiatric interns as well as a medical doctor during off-hours, three clinical nurse 
specialists, 6 licensed social workers, 2 psychologists, two licensed mental health counselors, 6 
occupational/rehabilitation therapists, several administrators, and numerous nurses working 
shifts around the clock (24/7).  
  The QI project participants consisted of six inpatient clients and 16 clinicians who were 
members of the multidisciplinary team on two chronic care wards (A2 and C3).  The clients' 
selection and participation in the QI project were coordinated by the psychiatry clinician 
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participants. Three clients with OUD were chosen from each of the assigned wards. The DNP 
student was not directly involved with the clients at any time during the study.  
The clinical staff inclusion criteria were based on their willingness and availability to participate 
in the project, commitment to complete the pre-and post-intervention questionnaires, and team 
participation. The criteria for exclusion included all staff that were not part of the treatment team, 
those who worked on an off-hours shift. Similarly, clients 18 years and under were excluded 
from the study as well as those that did not meet the DSM-V criteria for OUD.  
 Pre-Intervention  
The plan for the project began in the fall of 2019 through a conversation with a 
colleague and DNP student adviser about a DNP QI project. The DNP student then 
proceeded to do a literature search on opioid abuse sentinel episodes at the identified facility 
site before discussing them with the stakeholders. Also, the DNP student interviewed various 
clinical personnel in the area about the problem of opioid abuse and overdose at the facility, 
the disproportionate care, and how to improve treatment for psychiatric inpatient clients 
suffering from OUD.  The literature review identified evidence-based interventions that 
could be implemented to improve treatment for psychiatric patients with OUD. A 
PowerPoint training format on evidence-based opiate assessment scales was developed from 
the literature review to provide training to healthcare clinicians on Wards A2 and C3 of the 
project site.  
A letter of support was obtained January 2020 after the key stakeholders who consisted 
of the Facility Medical Director (FMD), the Chief Operating Officer, the Nursing Director, 
and the Chief of Psychiatry endorsed the implementation of the QI project.  The endorsement 
of the project by these key stakeholders energized the multidisciplinary clinicians on Wards 
A2 and C3 to participate in the QI performance.  
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Other stakeholders involved in the project were administrative staff and unit managers who 
assisted with dispensing the questionnaires and encouraged nursing staff and other participants to 
use the screening scales when assessing clients. These teams of experts provided profound 
contributions that led to the success of the project. As a result, numerous discussions were held 
between the team and the DNP student to review the specifics concerning the QI project 
planning.  
       The implementation of the project commenced in early November 2020. The DNP student 
presented an overview of the project to the participants on Wards A2/C3 and administered the 
pre-test survey prior to dispensing the educational training. The pre-test questionnaire (Appendix 
I) was developed by the DNP student to obtain information from the multidisciplinary team 
about their clinical strengths, weaknesses, and timely utilization of OUD screening scales during 
the admission evaluation and at other times when opiate abuse is suspected of triggering a 
change in a client’s mental status. The pre-test survey is a 5-point Likert type scale made up of 
ten questions with the answer selections of 1) strongly disagree, 2) disagree, 3) uncertain, 4) 
agree, and 5) strongly agree. Additionally, three of the pre-test questions address the screening 
scales and participants’ comfort level with using the scales, 4 questions focused on opioid abuse 
signs and symptoms and its negative effects on clients and 3 questions centered on evidence-
based recommendations to use MAT, counseling, and substance awareness group to treat clients 
with OUD. Moreover, the pre-test questionnaire was designed to illicit the knowledge and 
thoughts of the multidisciplinary team regarding the relevance and benefits of the timely referral 
of the identified OUD clients to treatment that consisted of MAT, individual counseling, and a 
substance awareness group. 
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Intervention 
The education intervention involved one power point presentation delivered on two 
separate units to the project participants at the psychiatric hospital through email. The 
PowerPoint presentation (Appendix M) addressed opioid abuse signs and symptoms, introduced 
the scales: Clinical Opiate Withdrawal Scale (COWS) and the Screening, Brief Intervention, 
Referral to Treatment (SBIRT) and explained the need for early assessment with the screening 
scales, provided training in the use of the scales, and addressed the referral of patients with OUD 
to medication-assisted treatment, a substance awareness group, and individual counseling.   
The presentation (Appendix M) included a thorough review of both the COWS and the 
SBIRT tools, which included the following information:  Clinical Opiate Withdrawal Scale 
(COWS) is an 11-item tool designated for implementation by healthcare practitioners to assess 
and monitor signs and symptoms of opiate withdrawal in inpatient and outpatient settings 
(Tompkins et al., 2009). The COWS tool was assessed to have a Cronbach's alpha of 0.78, 
indicating good internal consistency and reliability and a strong correlation rate of [r>0.5] 
(Tompkins et al., 2009). Also, the SBIRT tool was given an excellent internal reliability scale 
rate component (>85) and correlated validity rate[r=.45] (DiClemente et al., 2015).  Additionally, 
the Screening, Brief Intervention, and Referral to Treatment (SBIRT) tool is designed to provide 
early intervention and treatment for individuals diagnosed with substance abuse or clients at risk 
of displaying OUD (SAMHSA, 2017). Furthermore, copies of the screening scales were also 
distributed through an email message to the project participants. Likewise, supplemental 
materials on OUD signs and symptoms, and information on motivational interviewing were 
posted on poster boards in the staff break room, conference room, nurses’ stations on the units, 
and dining rooms.  
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       Following the presentation, clinicians were encouraged via email by this DNP student to 
utilize the screening scales for OUD on Wards A2 and C3 at the project site from November 
2020 to January 2021. The DNP student also engaged in discussions with the multidisciplinary 
team to gather feedback on the pros/cons and their perception of the QI project. This information 
was used to identify outliers during the implementation of the QI project evidence-based 
intervention.  
        Client Referrals and Interview: One of the project’s goals were to improve opioid abuse 
assessment, opioid abuse diagnosis, and the timely referral of identified clients to treatment and 
then to monitor the clients' change process. Consequently, six clients were identified by the four 
psychiatric clinicians for referral. They were referred to a treatment program that included MAT, 
a substance awareness group, and counseling intervention that incorporated motivational 
interviewing skills to spur patients along the stages of change trajectory.  
The clinical staff participants were encouraged to utilize the TTM tenets of change in 
monitoring their client's adherence to the MAT and psychotherapy intervention. The DNP 
student collected qualitative data from case briefs on client’s behavior change with the 
psychiatric clinicians centered on the patients’ compliance with specialty treatment. The 
interview questions addressed the timely referral of the identified clients to MAT, the 
commitment of the clients to MAT, their dedication to the substance awareness recovery group 
and to counseling, and their trajectory of change based on the tenets of the TTM.  
Post-Intervention 
Post-test questionnaire (Appendix J), developed by the DNP student was administered to 
all participants three months after implementing the evidence-based intervention to obtain 
participant perception on the educational intervention. The post-test survey also comprised ten 
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questions and had a 5-point Likert response of 1 to 5 like the variables answer choices in the pre-
test questionnaire. Two questions on the post-test questionnaire addressed the participants’ 
opinion about the educational intervention, 4 questions were asked to assess their confidence 
level with the screening scales, 2 questions addressed OUD treatment and 2 questions focused on 
consistency with using the scales. Overall, the post-test survey evaluated the participants’ view 
on the education intervention, how often clinicians used the screening scales, their 
comfortability/confidence level with using the scales, engagement of client in treatment 
modalities and self-report of influence on client behavior change. Furthermore, the DNP student 
dispensed the post-intervention evaluation questionnaire to gather data about the quality 
improvement project implementation.  
Data Analysis  
      Descriptive statistics were utilized to analyze the quantitative data from the 
questionnaires. The mean and standard deviation of the responses from the pre-test and post-
test questionnaires were calculated and organized on a Microsoft Excel spreadsheet 
(Appendices K & L). Individual answers to questions were assessed for variations in 
knowledge and graded on a percentage criterion. One hundred percent was the maximum 
score, and zero percent was the lowest possible score. The difference between the pre and 
post-test scores per participant was presented on a run chart. The interview data on case 
briefs about the patient change in behavior related to adherence to MAT and the substance 
awareness psychotherapy intervention and counseling were examined in themes for the 
report. Tables 4 and 5 (Appendices K and L) contain the descriptive statistics of the pre-and 
post-test scores in terms of percentages.  
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Ethical Considerations/Protection of Human Subjects 
Before implementing the project, the DNP student forwarded a human subject 
determination form to the University of Massachusetts Amherst Human Research Protection 
Office Internal Review Board (IRB) to obtain consent. The IRB reviewed the project and 
decided that the project did not meet the federal regulatory definition of a human subject study 
and therefore did not require approval from the IRB (Appendix D). Likewise, the project site did 
not require IRB assent. Indeed, the members of the board were in full support of this project, as it 
is a quality improvement project. A letter of support was also obtained from the project site 
medical director. 
The main goal of the QI project was to provide education about standardized opioid use 
disorder assessment scales. It included assessing the consistent utilization of these tools and 
implementing evidence-based, multifaceted recommendations based on the literature that 
includes early referral to MAT, counseling, psychotherapy intervention for opioid abuse, and 
monitoring clients with OUD through the stages of the behavior change trajectory. As stated 
previously, the DNP student was not directly involved with the clients.  
       The data was gathered solely from the scores of the five-point Likert pre-intervention and 
post-intervention questionnaires and open-ended case briefs interviews with clinicians about the 
consistency with using these assessment scales and the client's compliance with treatment. The 
DNP student did not have access to electronic information about the human subject sample. The 
interview discussions with clinicians about the clients identified with OUD and treatment 
modalities strictly adhered to the Health Insurance Portability and Accountability Act of 1996 
(HIPAA) confidentiality standard and hospital laws and privacy procedures. The private 
information of the participants was de-identified, and case numeric identification figures and 
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letters were allocated to the clinicians and their clients as a replacement for initials during the 
data storage process (Chevrier et al., 2019).  
Results 
The QI project for opioid use was implemented on two units of a 320-bed inpatient public 
psychiatric hospital in western Massachusetts from November 2020 to January 2021. The 
participants who implemented the intervention were mental health clinicians who were members 
of the multidisciplinary treatment team and worked with patients with chronic psychiatric 
disorders. The QI project participants consisted of psychiatry providers, psychologists, social 
workers, occupational therapists, registered nurses, and a licensed mental health counselor. A 
total of 20 participants were initially selected for the educational session and implementation of 
the screening scales. However, only 16 (N=16) participants completed both pre and post-test 
questionnaire and implemented the scales. In addition, four psychiatry clinician participants 
attended the case brief interview sessions on monitoring and reporting the change process of six 
patients with OUD. The number of participants that took the pre-test and post-test survey and the 
classification of their various disciplines are presented in Table 1. 
Table 1  
Classification of the Disciplines of the Project Participants     
Discipline  Participants               Percentage  
Psychology  2  11.76%  
Psychiatry  4                         23.53%  
Nursing  3                        17.64%  
OT/Rehab  1                        5.88%  
LMHC  1                 5.88%  
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      Most of the participants who completed the questionnaires were non-nursing mental health 
care clinicians. Of the 16 mental health care providers, 29.41% (n= 5) were licensed clinical 
social workers, 23.53% (n= 4) were psychiatrists or psychiatric mental health nurse practitioners, 
and 5.88% (n=1) were occupational/rehabilitation therapists. Similarly, 11.76% (n=2) of the 
participants were psychologists and one was a licensed mental health counselor (5.88%). Of the 
16 project participants, only 17.64% (n=3) were registered mental health nurses. 
The data collected by the inquiry will be examined in the following sections, which are 
illustrated by the descriptive statistics from Tables 4 and 5 (Appendices K and L). A run chart 
was also used to compare the participants' responses to the pre and post-test questionnaires 
(Figure 1, pg. 30). 
The pre-test intervention questionnaire revealed a need for knowledge concerning 
assessing, identifying, and managing clients with opioid abuse disorder. The pre-test 
questionnaire's highest score was 94%, while the lowest score was 25% and the average score 
was 50%. Only 31% (n= 5) of the participants exhibited confidence in using the screening scales. 
From the 16 participants, only 25% (n=4) noted that they were familiar with opioid abuse signs 
and symptoms. Eighty-one percent of the participants (n=13) indicated that they needed more 
information about opioid abuse signs and symptoms. In comparison, 38% of the participants 
(n=6) agreed they felt confident in their ability to use the screening scales. Fifty percent (n= 8) of 
the participants agreed that they were comfortable with their knowledge of medication-assisted 
treatment for OUD. In comparison, 38% (n=6) decided that it is essential to discuss such 
treatment with their identified OUD clients before referring them to specialty treatment and 94% 
Social Work  5                           29.41%  
Other  0               0.0%  
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(n=15) agreed that they needed more information and education about opioid use disorder 
screening scales.  
       The post-test questionnaire uncovered an increase in knowledge about opioid abuse signs 
and symptoms and participants reported an increase in confidence in using the screening 
scales to identify OUD clients and promptly referring patients to specialty treatment. The 
highest score in the post-test questionnaire was 100% while the lowest score was 63%. The 
average score was 88%. Ninety-four percent of the participants (n=15) agreed that 
knowledge was gained from the educational presentation and 93.8% (n=15) indicated that 
they were well informed about OUD signs and symptoms.  
        Similarly, 81.3% (n=13) agreed that their confidence to use the screening scales 
increased after the PowerPoint presentation and 87.5% (n=14) indicated that they felt more 
confident about engaging clients using SBIRT and counseling with motivational interviewing 
techniques. Furthermore, 93.7% (n=15) agreed that the educational intervention increased 
their knowledge about MAT, counseling, and substance awareness group, while 87.5% 
(n=14) indicated that the project intervention enhanced their ability to provide counseling to 
clients and facilitated prompt identification of OUD clients and referral process to treatment.    
       The lowest score in the post-test questionnaire was 63% (n=10) of participants who 
agreed that they consistently used the screening scales to evaluate new intakes during the 
admission process. One hundred percent of the participants (n=16) agreed that they 
benefitted from the project intervention. However, 93.75% of the participants (n=15) agreed 
that they would continue to use the information from the QI project to make changes in their 




Comparison Between Pre and Post Test Scores per Participant 
 
 
      The above data revealed a constructive improvement in the post-test score in all 
participants. Additionally, most of the post-test questionnaire participants had scores > 80% 
(n=15) of increase in test scores which means increased knowledge was obtained from the 
education intervention. Likewise, the post-test participants more than doubled their scores. 
Figure 1 illustrates comparison scores for each participant in the pre-test and post-test 
questionnaires. 
Results, Case Briefs on Behavior Change of Clients 
      The DNP student conducted two successful 15-minute individual case brief interview 
sessions with four psychiatry clinicians on the multidisciplinary team to ascertain the 














Pre and Post Test Questionnaire Scores
Pre test questionnaire post test questionnaire
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conducted in January 2021 prior to the administration of the post-test survey. After meeting 
with the psychiatry clinicians, the responses revealed encouraging results. The clinicians 
described the impact of the educational intervention as successful, as evidenced by the 
enrollment of four clients in medication-assisted treatment (MAT) and the remaining two 
clients still waiting to start Buprenorphine treatment. Also, all six patients participated in a 
substance awareness recovery group and counseling during the project implementation. 
Furthermore, two clinicians noted a substantial change in the clients’ behavior due to 
improved insight into the risk of opioid abuse and MAT. Moreover, it was mentioned that the 
clients gained insight into their risky behavior through adherence to psychotherapy groups 
and individual counseling from their psychiatry clinicians. 
Therapy was also reported to have positive results in that, clinicians reported that 
clients with access to both MAT and psychotherapy intervention for substance 
awareness/counseling made drastic progress on the change trajectory based on the TTM. In 
fact, according to the four psychiatry clinicians, MAT possibly contributed to the eradication 
of complaints and craving for illicit opiates by the four clients who were engaged in MAT, 
while the substance awareness and psychotherapy/counseling interventions helped the clients 
develop insight into their previous risky behavior of abusing opiates. Most clinicians noted 
that incidents of opioid abuse and overdose were significantly reduced by ninety percent 
except for one incident during the implementation of the QI project on Wards A2 and C3, as 
evidenced by reports from the daily rounds. In addition, all four clinicians agreed that the 
patient participants were motivated to change. Four out of the six clients who participated in 
the QI project stated that they will continue to engage in specialty treatment for OUD after 
discharge from the inpatient facility. 
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                                                      Discussion 
The QI project for opioid use disorder took place on two units at a psychiatric hospital in 
western Massachusetts. The QI project implementation provided multifaceted evidence-based 
education to mental health professionals at the project site both by emailed presentations and in 
person case debriefs. The goal of the QI project was to improve opioid abuse assessment, 
diagnosis, and early referral of identified clients to treatment and to monitor the change process 
of six patients who engaged in specialty treatment three months after the implementation of the 
screening scales. 
      Through education, coaching, and early referral to specialty treatment, clinical providers can 
enhance the quality of life of clients struggling with OUD (CDC, 2016). Prior to the PowerPoint 
educational presentation, all participants completed a pre-test questionnaire to examine their 
thoughts about OUD, the screening scales, and treatment that includes MAT, individual 
counseling, and substance awareness groups. The results demonstrated that there was an 
improvement in knowledge after the educational PowerPoint presentation. 
 The pre-test and post-test surveys had good participation, with 16 mental health care 
providers completing them. Although the number of participants was small (n=16), the project 
result was consistent with the literature regarding the benefits and sustainability of using OUD 
screening scales such as the COWS and SBIRT to identify clients and prompt referrals for 
specialty treatment.  The finding from the review of the literature revealed that evidence-based 
practice should include counseling with motivational interviewing skills, clinical judgment, and 
easy access to MAT for patients with OUD (CDC, 2016).  
The US Preventative Service Task Force [USPSTF] (2019) recommends opioid use 
disorder treatment, which involves assessing the use of illicit drugs, the misuse of prescription 
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drugs, and the subsequent referral for intervention to counteract drug abuse. Moreover, the 
COWS is designated for clinicians to assess and monitor for signs and symptoms of opiate 
withdrawal in inpatient and outpatient settings (Tompkins et al., 2009), and several studies 
recognize the COWS as reliable (Wesson & Ling, 2003). Similarly, the SBIRT tool is designed 
to address early intervention and treatment for individuals diagnosed with substance abuse or 
clients at risk of displaying OUD (SAMHSA, 2017).  
The intervention improved patient outcomes in the inpatient psychiatric hospital by 
increasing the clinical team's knowledge to detect and empower clients to engage in specialty 
treatment. Rosenthal et al. (2018) revealed a knowledge gap about clinicians’ comfortability with 
using the COWS and SBIRT screening scales in assessing OUD clients in the inpatient setting. 
This is in line with what the DNP student discovered during the implementation process. The 
pre-test intervention questionnaire revealed a need for knowledge about assessing, identifying, 
and managing clients with opioid abuse disorder. As previously mentioned, 31% (n= 5) of the 
participants exhibited confidence in using the screening scales, 25% (n=4) noted that they were 
familiar with opioid abuse signs and symptoms, and 81% of the participant (n=13) indicated that 
they needed more information about opioid abuse signs and symptoms.  
The post-test intervention questionnaire uncovered an increase in knowledge concerning 
opioid abuse signs, symptoms, and confidence in using the screening tools to identify OUD 
clients and the timely referral of patients to specialty treatment. Consequently, 100% (n=16) of 
the post-test participants agreed that their clinical practice and patients benefitted from the 
educational presentation and the implementation of the screening scales. As a result of the 
educational intervention and implementation, six clients with OUD were appropriately identified 
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and referred to medication-assisted treatment, counseling and completed the substance awareness 
recovery group.  
In addition, the four identified clients were educated by their clinicians about the risk of 
opioid abuse and the benefits of engaging in specialty treatment that can lead to optimal 
wellbeing. The clients' change process was initiated and evaluated by the mental health providers 
through the transtheoretical model (TTM) of behavior change. Prochaska et al. (1992) noted 
people's intentionality in the changing paradigm.  The study authors also noted that individuals 
were observed as advancing linearly through the stages of pre-contemplation, contemplation, 
preparation, action, and maintenance before termination. The TTM demonstrates an 
understanding of when shifts in the opinions and objectives of clients occur (Prochaska et al., 
1992). In this way, the clinicians at the project site expressed that they observed their clients' 
shifts in attitude and behavior as indicated by the TTM as they engaged in specialty treatment.   
The project participants reported that they will continue to use the knowledge from the 
educational intervention and the OUD screening scales in their clinical practice. Most of the 
providers noted that opioid abuse and overdoses were significantly reduced during the QI project 
implementation on Wards A2 and C3 at the project site. Also, the post-test questionnaire scores 
demonstrated knowledge gained in that 100% (n=16) of the participants agreed that they 
benefitted from the educational intervention and implementation of the scales. The interview 
data from the clinicians about their clients indicated that the implementation of the screening 
scales aided the identification of clients during intake assessment with OUD and fostered a 
timely referral to specialty treatment.  
  The strengths of the QI project included the support of the stakeholders and 
multidisciplinary team members on Wards A2 and C3. Additional strengths were access to 
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providers with prescription authority, access to counseling and psychological resources, and 
access to available materials that can be used by providers, patients, and the community to 
expedite education.   
 A significant barrier during the implementation of the QI project implementation was the 
Covid-19 pandemic and the surge of positive cases of infection at the project site. As a result, the 
facility administration established restrictive protective policies that increased the DNP student's 
timeframe at the project site due to the participants’ absentee rate either from being sick from the 
virus or quarantining at home after exposure to the virus. Likewise, due to the coronavirus 
pandemic, very few patients were admitted or transferred from other facilities. Thus, 62.5% of 
the participants (n=10) agreed in the post-test survey that they could not consistently use the 
OUD screening scales in their clinical assessment of patients. However, 93.75% of the 
participants (n=15) agreed that they would continue to use the information from the QI project to 
make changes in their practice. Both clinician and client participants expressed that the QI 
project was successful, and several clinicians expressed a plan to integrate the knowledge gained 
into their clinical practice. 
Implications and Recommendations 
      This project emphasized the importance of addressing a specific patient population within the 
psychiatric hospital setting. Velez et al. (2016) concisely concluded that inpatient hospitalization 
is an appropriate timeframe to successfully reach patients who are indicated for substance abuse 
treatment, as they may comprehend that substance abuse has harmfully affected their wellbeing. 
According to the USPSTF (2019), the recommendation for opioid use disorder (OUD) treatment 
involves assessing the patient for the use of illicit drugs and the misuse of prescription drugs and 
providing referral for intervention to counteract drug abuse. The QI project implemented opioid 
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abuse scales to identify and refer patients with OUD to MAT and monitor behavior change with 
the tenets of the transtheoretical model (TTM). The TTM is an essential deliberate framework 
for monitoring improvement in behavior change, especially in addiction treatment. The clinical 
providers explored the tenets obtained from the model to monitor behavior change and practice 
improvement successfully. As indicated by the data collected in the case brief interviews with 
clinicians, the patient participants were motivated to change.  
       The significance of additional study into the occurrence of OUD and appropriate utilization 
of the screening scales to promptly identify and refer clients within a facility for treatment is 
essential. Educating clinical providers on an ongoing basis to properly assess, diagnose, and refer 
psychiatric clients with OUD to specialty treatment that includes medication-assisted treatment, 
counseling, and a substance awareness group is crucial to reducing hospitalization. The QI 
project was implemented successfully on two units in a psychiatric hospital. It is recommended 
that the findings of the project be extrapolated to other wards in the facility. Van Hoeven et al. 
(2015) expressed that a predetermined diminutive sample size can be utilized to represent a large 
target population. Similarly, the screening scales should be included in the electronic health 
record intervention to be completed by healthcare providers for all clients during admission 
evaluation. Also, efforts should be made on an ongoing basis to ensure that psychiatric facilities 
incorporate current evidence-based treatments and modalities to manage clients with OUD 
better. 
                                                            Conclusion 
The timely evaluation and treatment of patients with OUD at a psychiatric hospital are 
essential. The evidence-based literature shows that a combination of early assessment to identify 
clients with OUD, medication, and psychotherapy intervention can successfully treat patients 
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struggling with OUD (SAMHSA, 2021). Velez et al. (2016) concluded that inpatient 
hospitalization is an appropriate timeframe to successfully reach patients who are indicated for 
substance abuse treatment, as they may comprehend that substance abuse has negatively affected 
their wellbeing. Hence, appropriate assessment/treatment should be addressed and initiated 
concurrently in the inpatient hospital setting. Evidence-based findings from the literature review 
revealed that a multifaceted intervention approach that consists of appropriate assessment with 
standardized OUD tools, early referral to medication-assisted treatment, counseling, and 
psychotherapy intervention for substance awareness is needed to combat the opioid abuse crisis.  
Consequently, the QI project implemented a comprehensive, evidence-based clinical 
intervention to improve the assessment, diagnosis, and treatment of adult patients suffering from 
OUD in the inpatient psychiatric hospital setting. This project's findings substantiate an overall 
increase in the knowledge of how to enhance the care of hospitalized psychiatric patients 
suffering from OUD. The implementation of the QI project improved the clinical skills of the 
multidisciplinary team members regarding how to use the screening scales to identify clients 
with OUD to enhance the process of the referral of patients to specialty treatment. In addition, 
the QI project facilitated the patients’ knowledge about the risk of opioid abuse and the need to 
remain in specialty treatment within the hospital and after discharge.  
      The project positively impacts the facility regarding managing patients with OUD in an 
inpatient psychiatric hospital setting. This project emphasizes the importance of addressing a 
specific patient population within the psychiatric hospital setting. Further study needs to be 
conducted to find ways to tackle the needs of patients with co-occurring mental illness and OUD. 
However, the project's findings could help increase measures to manage inpatient psychiatric 
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clients suffering from OUD and reduce emergency department evaluation/treatment, unforeseen 
hospitalizations due to overdose from opioids, and readmissions.                                           
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  Appendices 
Appendix A 
Figure 2: Stages of Change 
 





Itemized Details of Cost-Benefit 
Items  Cost in Dollars 
Copy and printing paper for survey, training session, 
handouts 
40.00 
Toner cartridge for printer 40.00 
Office supplies: Pack of pens, folders 20.00 
Conference room allocated for training session, 
office space and bill 
0.00 (provided by facility) 
Clinical staff  0.00 (provided by facility) 
 Laptop 00.00 (provided by DNP student) 
Time for staff training 00.00 
Light refreshment pre-Covid19 pandemic surge 100.00 
Total cost for quality improvement project 200.00 
 
 








Itemized Details of QI Project Timeline 
Timeline Itemized Details of QI Project 
 
Week 1 
Following approval of proposal. 
Provide details of the DNP QI proposal to 
facility stakeholders and obtain a letter of 
support. 
Week 2 
Provide an overview of the QI project proposal 
to clinical personnel on ward A2 and C3 and 
administer the pre-test questionnaires. 
 Week 3 
Provide training sessions on COWS and SBIRT 
and implement the screening toolkits in assessing 
patients for OUD during intake evaluation. 
Weeks 4 – 11 
Monitor a consistency in implementing COWS 
and SBIRT and referral of patients to MAT and 
substance abuse groups 
Week 9 
 Conduct 1:1 interview with clinical personal to 
evaluate stages of behavior change among clients 
with OUD 
Week 10 
Conduct 1:1 interview with clinical personal to 
evaluate stages of behavior change among clients 
with OUD 
Week 11 
Conduct 1:1 interview with clinicians to evaluate 
compliance with MAT/psychotherapy 
intervention 
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                                                                                                                                                                                                                               Hadley, MA 01035  








Memorandum – Not Human Subjects Research Determination   
 
 
Date: November 6, 2020  
  
To:  Pauline Eteng, College of Nursing  
  
Project Title: A performance Improvement Project for Opioid Abuse Disorder on a Chronic Care 
Psychiatric Hospital in Western MA  
  
HRPO Determination Number: 20-235  
  
The Human Research Protection Office (HRPO) has evaluated the above named project and has made 
the following determination based on the information provided to our office:  
  
☐ The proposed project does not involve research that obtains information about living individuals  
[45 CFR 46.102(f)].  
  
☐ The proposed project does not involve intervention or interaction with individuals OR does not use 
identifiable private information [45 CFR 46.102(f)(1), (2)].  
  
☒ The proposed project does not meet the definition of human subject research under federal regulations 
[45 CFR 46.102(d)].  
  
Submission of an Application to UMass Amherst IRB is not required.  
  
Note: This determination applies only to the activities described in the submission. If there are changes 
to the activities described in this submission, please submit a new determination form to the HRPO prior 
to initiating any changes. Researchers should NOT include contact information for the UMass 
Amherst IRB on any project materials.  
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A project determined as “Not Human Subjects Research,” must still be conducted ethically. The UMass 
Amherst HRPO strongly expects project personnel to:  
  
- treat participants with respect at all times  
- ensure project participation is voluntary and confidentiality is maintained (when applicable)  
- minimize any risks associated with participation in the project   
- conduct the project in compliance with all applicable federal, state, and local regulations as well 
as UMass Amherst policies and procedures, which may include obtaining approval of your 
activities from other institutions or entities.  
  
Please do not hesitate to call us at 413-545-3428 or email humansubjects@ora.umass.edu if you have 
any questions.  
  
  
Iris L. Jenkins, Assistant Director  

















Clinical Opiate Withdrawal Scale (COWS) 
Flowsheet for measuring symptoms for opiate withdrawals over a period 
For each item, write in the number that best describes the patient’s signs or symptoms. Rate on 
just the apparent relationship to opiate withdrawal. For example, if the heart rate is increased 
because the patient was jogging just prior to assessment, the increased pulse rate would not add 
to the score. 
 
 
Patient’s Name:   Date:    
Enter scores at time zero, 30min after first dose, 2 h after first dose, etc. 
Times:             
Resting Pulse Rate: (record beats per minute) 
Measured after patient is sitting or lying for one minute 
1 pulse rate 80 or below 
2 pulse rate 81-100 
3 pulse rate 101-120 
4 pulse rates greater than 120 
     
Sweating: over the past ½ hour not accounted for by room 
temperature or patient activity. 
1 no report of chills or flushing 
2 subjective report of chills or flushing 
3 flushed or observable moistness on face 3 beads of 
sweat on brow or face 
4 sweat streaming off face 
     
Restlessness Observation during assessment 0 able to 
sit still 
1 reports difficulty sitting still, but is able to do so 
3 frequent shifting or extraneous movements of legs/arms 5 Unable to 
sit still for more than a few seconds 
     
Pupil size 
1 pupils pinned or normal size for room light 
2 pupils possibly larger than normal for room light 2 pupils 
moderately dilated 
5 pupils so dilated that only the rim of the iris is visible 
     
Bone or Joint aches If patient was having pain previously, only the 
additional component attributed to opiates withdrawal is scored 
1 not present 
2 mild diffuse discomfort 
3 patient reports severe diffuse aching of joints/ muscles 4 patient is 
rubbing joints or muscles and is unable to sit 
still because of discomfort 




Runny nose or tearing Not accounted for by cold symptoms 
or allergies 
1 not present 
2 nasal stuffiness or unusually moist eyes 2 nose 
running or tearing 
4 nose constantly running or tears streaming down cheeks 
    
GI Upset: over last ½ hour 
0 no GI symptoms 1 stomach 
cramps 
2 nausea or loose stool 3 vomiting 
or diarrhea 
5 Multiple episodes of diarrhea or vomiting 
    
Tremor observation of outstretched hands 
1 No tremor 
2 tremor can be felt, but not observed 2 slight 
tremor observable 
4 gross tremor or muscle twitching 
    
Yawning Observation during assessment 
1 no yawning 
2 yawning once or twice during assessment 
3 yawning three or more times during assessment 4 yawning 
several times/minute 
    
Anxiety or Irritability 
1 none 
2 patient reports increasing irritability or anxiousness 2 patient 
obviously irritable anxious 
4 patient so irritable or anxious that participation in the assessment is 
difficult 
    
Gooseflesh skin 
0 skin is smooth 
3 piloerections of skin can be felt or hairs standing up on arms 
5 prominent piloerections 
    
Total scores with observer’s initials     
Score: 
5-12 = mild 
13-24 = moderate 
25-36 = moderately severe 
more than 36 = severe withdrawal 








Figure 3: Screening, Brief Intervention, and Referral to Treatment (SBIRT) Scale 
 
                     
 
 
                                 
Note: Flow Chart of Screening, Brief Intervention, and Referral to Treatment (SBIRT) in 
Practice (Wright et al., 2016).                                                    
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Appendix G 
Figure 4: Motivational Interviewing Technique 
 
Note: Motivational Interviewing: Helping People Change (Miller & Rollnick, 2013). 
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Appendix H 
Figure 5: What is SBIRT 
 
 






Participants’ Initials:  
Please select only one of the appropriate responses that best explain your thoughts on the choices 
below. 
1. I feel confident in my abilities to use the Clinical opiate withdrawal scale in evaluating 
my clients during admission. 
1 2 3 4 5 
Strongly Disagree Disagree Uncertain Agree Strongly Agree 
 
2. I am familiar with opiate overdose signs and symptoms. 
1 2 3 4 5 
Strongly Disagree Disagree Uncertain Agree Strongly Agree 
 
3. I need more information about opiate overdose signs and symptoms. 
1 2 3 4 5 
Strongly Disagree Disagree Uncertain Agree Strongly Agree 
 
4. I am aware that opioid abuse can negatively impact a patient’s health and lead to 
overdose and death. 
1 2 3 4 5 
Strongly Disagree Disagree Uncertain Agree Strongly Agree 
   
5. I feel confident in my ability to use the screening, brief intervention, and referral to 
treatment toolkit during intake assessment and when clients exhibit a change in mental 
status related to opioid abuse. 
1 2 3 4 5 
Strongly Disagree Disagree Uncertain Agree Strongly Agree 
 
6. I feel confident in my abilities to do brief intervention counseling about opioid abuse 
during intake assessment and at other times to identify clients with opioid abuse in order 
to refer them for treatment. 
1 2 3 4 5 
Strongly Disagree Disagree Uncertain Agree Strongly Agree 
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7. I am aware of evidence-based recommendation procedures to treat patients with opioid 
use disorder. 
1 2 3 4 5 
Strongly Disagree Disagree Uncertain Agree Strongly Agree 
 
8. I feel comfortable in my knowledge about medication assisted treatment for opioid use 
disorder. 
1 2 3 4 5 
Strongly Disagree Disagree Uncertain Agree Strongly Agree 
 
9. When a client is assessed as meeting criteria for opioid use disorder according to DMS-V 
stipulations; I think it is important to discuss with them prior to referring them to 12 step 
meetings, SMART program or DBT for substance awareness. 
1 2 3 4 5 
Strongly Disagree Disagree Uncertain Agree Strongly Agree 
 
10. I need more information and education about opioid use disorder toolkits. 
1 2 3 4 5 


















Participants’ Initials:  
Please select only one of the appropriate responses that best explain your thoughts on the choices 
below. 
1. I feel that I learned from the PowerPoint presentation on opioid use disorder toolkit. 
1 2 3 4 5 
Strongly 
Disagree 
Disagree Uncertain Agree Strongly Agree 
 
2. I am well informed about opioid overdose signs and symptoms. 
1 2 3 4 5 
Strongly 
Disagree 
Disagree Uncertain Agree Strongly Agree 
 
3. I have been using the toolkits for intake assessment and for patients that exhibit mental 
status changes in the milieu after the PowerPoint presentation session 
1 2 3 4 5 
Strongly 
Disagree 
Disagree Uncertain Agree Strongly Agree 
     
      4.   My confidence to use the toolkit to assess clients with opioid use disorder increased after    
             the educational session. 
1 2 3 4 5 
Strongly 
Disagree 
Disagree Uncertain Agree Strongly Agree 
 
         5. After participating in this QI project, I feel more confident about my ability to engage      
              clients for brief counseling with motivational interviewing skills 
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1 2 3 4 5 
Strongly 
Disagree 
Disagree Uncertain Agree Strongly Agree 
 
          6. Participating in this project increased my knowledge about medication-assisted           
               treatment and psychotherapy intervention. 
1 2 3 4 5 
Strongly 
Disagree 
Disagree Uncertain Agree Strongly Agree 
 
           7.  Participating in this project increased my ability to provide brief counseling about the   
                 dangers of opioid abuse prior to referring identified clients to specialty treatment. 
1 2 3 4 5 
Strongly 
Disagree 
Disagree Uncertain Agree Strongly Agree 
 
            8.  I have consistently used the opioid use disorder toolkit in my clinical assessment after  
                 attending the educational presentation sessions. 
1 2 3 4 5 
Strongly 
Disagree 
Disagree Uncertain Agree Strongly Agree 
 
           9.   I feel that my clinical practice and patients benefited from the educational     
                 presentation. 
1 2 3 4 5 
Strongly 
Disagree 
Disagree Uncertain Agree Strongly Agree 
  
         10.  I will continue to use the information from the performance improvement project to     
               make changes in my clinical practice. 
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1 2 3 4 5 
Strongly 
Disagree 








Descriptive Statistics of Pre-Test Scores for Opioid Abuse and Opioid Screening Knowledge 
Areas (N=16) 
 Number Mean Std 
Deviation 
Percentages 
I feel confident in my abilities to use the Clinical 
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Descriptive Statistics of Post-Test Scores for Opioid Abuse and Opioid Screening Knowledge 
Areas (N= 16) 
 Number Mean Std 
Deviation 
Percentages 
I feel that I learned from the PowerPoint 
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                                                         Appendix M 
Opioid Use Disorder Education PowerPoint 
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